专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明授权

US5443972A Process to prepare leustroducsins 失效
标题翻译：制备leustroducsins的过程
公开(公告)号：US5443972A
公开(公告)日：1995-08-22
申请号：US239284
申请日：1994-05-06
申请人： Takafumi Kohama , Isao Kaneko , Takemichi Nakamura , Takeshi Kagasaki , Ryuzo Enokita , Keiichi Matsuda
发明人： Takafumi Kohama , Isao Kaneko , Takemichi Nakamura , Takeshi Kagasaki , Ryuzo Enokita , Keiichi Matsuda
IPC分类号： C07D309/38 , A61K31/655 , A61K31/665 , A61P7/00 , A61P31/10 , C07F9/117 , C07F9/655 , C12N1/14 , C12P9/00 , C12P17/06 , C12R1/465
CPC分类号： C07F9/6552 , C12P17/06 , Y10S435/903
摘要： New compounds, which we have named the "Leustroducsins" have the formula (I): ##STR1## in which R represents a 5-methylhexanoyloxy group, a 6-methyloctanoyloxy group or a 7-methyloctanoyloxy group, and salts thereof, and may be prepared by fermentation using a microorganism of the genus Streptomyces, especially a strain of the species Streptomyces platensis, such as strain SANK 60191 (FERM BP-3288). These compounds may be used for the treatment or prophylaxis of: adverse reactions resulting from cancer chemotherapy or radiotherapy; infections; cancer; cerebral dysfunction; and fungal infections.
摘要翻译：我们命名为“雷诺霉素”的新化合物具有式（I）：其中R表示5-甲基己酰氧基，6-甲基辛酰氧基或7-甲基辛酰氧基的式（I）及其盐，并且可以通过使用链霉菌属的微生物，特别是品种Streptomyces platensis的菌株如菌株SANK 60191（FERM BP-3288）的发酵来制备。这些化合物可用于治疗或预防：由癌症化疗或放射治疗引起的不良反应; 感染; 癌症; 脑功能障碍; 和真菌感染。

12. 发明授权

US3907643A Process for producing the antibiotic U-44,590 失效
标题翻译：生产抗生素U-44,590的方法
公开(公告)号：US3907643A
公开(公告)日：1975-09-23
申请号：US54134675
申请日：1975-01-15
申请人： UPJOHN CO
发明人： DEBOER CLARENCE , BANNISTER BRIAN
IPC分类号： C07H19/12 , C12D9/00
CPC分类号： C07H19/12 , Y10S435/852 , Y10S435/903
摘要： New antibiotic U-44,590 and derivatives thereof, produced by the controlled fermentation of the new microorganism Streptomyces platensis var. clarensis var nova, NRRL 8035. This antibiotic and its derivatives are active against Gram-negative bacteria. Accordingly, they can be used in various environments to eradicate or control such bacteria.
摘要翻译：新型抗生素U-44,590及其衍生物，通过新型微生物链霉菌Streptomyces platensis var。这种抗生素及其衍生物对革兰氏阴性菌具有活性。因此，它们可以用于各种环境中以消除或控制这些细菌。

13. 发明授权

US3592925A Antibiotics ah272alpha2 and ah272beta2 and process for producing same 失效
标题翻译：抗生素AH272ALPHA2和AH272BETA2及其生产方法
公开(公告)号：US3592925A
公开(公告)日：1971-07-13
申请号：US3592925D
申请日：1969-04-21
申请人： AMERICAN CYANAMID CO
发明人： EVANS RALPH HENRY JR , THOMAS SAMUEL OWEN
IPC分类号： A61K21/00
CPC分类号： A61K31/70 , Y10S435/903
摘要： THIS DISCLOSURE DESCRIBES TWO NEW ANTIBIOTICS, DESIGNATED AH272A2 AND AH272B2, PRODUCED IN A MICROBIOLOGICAL FERMENTATION UNDER CONTROLLED CONDITIONS USING A NEW STRAIN OF STREPTOMYCES PLATENSIS AND MUTANTS THEREOF. THE NEW ANTIBIOTICS ARE ACTIVE AGAINST GRAM-POSITIVE BACTERIA AND THUS ARE USEFUL IN INHIBITING THE GROWTH OF SUCH BACTERIA WHEREVER THEY MAY BE FOUND.

14. 发明授权

US3520778A Microbiological demethylation process 失效
标题翻译：微生物化学方法
公开(公告)号：US3520778A
公开(公告)日：1970-07-14
申请号：US3520778D
申请日：1966-11-18
申请人： ROUSSEL UCLAF
发明人： BELLET PAUL , THUONG TRUONG VAN
IPC分类号： C07D459/00 , C07D471/22 , F15D1/02 , C12D13/00
CPC分类号： C07D459/00 , F15D1/02 , Y10S435/886 , Y10S435/897 , Y10S435/899 , Y10S435/903 , Y10S435/904

15. 发明授权

US3159552A Process of producing 4-dedimethylamino-4-methylethylamino-5-hydroxytetracycline 失效
标题翻译： 4-脱二甲基氨基-4-甲基乙基氨基-5-羟基四环素的制备方法
公开(公告)号：US3159552A
公开(公告)日：1964-12-01
申请号：US28285363
申请日：1963-05-24
申请人： AMERICAN CYANAMID CO
发明人： ANDREW MILLER PHILIP , COREY JR HOWARD SEEBREE
IPC分类号： C12P29/00
CPC分类号： C12P29/00 , Y10S435/898 , Y10S435/903 , Y10S435/904

16. 发明授权

US2996499A Cosynthetic factor-1, and its production 失效
标题翻译：合成因子-1及其生产
公开(公告)号：US2996499A
公开(公告)日：1961-08-15
申请号：US74342458
申请日：1958-06-20
申请人： AMERICAN CYANAMID CO
发明人： DANIEL MCCORMICK JERRY ROBERT , HAZLETT ARNOLD NANCY , URSULA HIRSCH , ANDREW MILLER PHILIP , OSCAR SJOLANDER NEWELL
IPC分类号： C12P1/06
CPC分类号： C12P1/06 , C12R1/485 , Y10S435/886 , Y10S435/887 , Y10S435/889 , Y10S435/897 , Y10S435/898 , Y10S435/903 , Y10S435/904
摘要： The invention relates to Cosynthetic Factor-1 (CF-1) and a process for the production of a tetracycline antibiotic by growing under aerobic conditions in an aqueous nutrient medium in the presence of CF-1 a culture of a species of Streptomyces which produces said antibiotic. CF-1 is produced by cultivating a CF-1 producing strain of Streptomyces in an aqueous nutrient medium containing assimiliable sources of carbohydrate, nitrogen and inorganic salts under submerged aerobic conditions until substantial CF-1 activity is imparted to said medium, filtering the fermentation mash at pH 6 to 7 and recovering CF-1 from the aqueous filtrate. It is preferred to use Streptomyces aureofaciens W5 (ATCC 13190), described, but others specified are S. albus, S. rimosus NRRL 2234, S. platensis NRRL 2364, S. hygroscopicus, S. viridifaciens ATCC 11989, S. griseus (streptomycin) and S. albo-niger (puromycin). The broth filtrate is adjusted to pH 8-9, saturated with ammonium sulphate, a carrier particularly a long chain alkyltrimethylammonium chloride added and the mixture is extracted with an alkanol such as butanol. The extract is adjusted to pH 1.5 to 2.0 with hydrochloric acid and back extracted with water. The aqueous phase is concentrated, chromatographed on diatomaceous earth and developed with buffered n-butanol. CF-1 rich cuts are extracted with water, concentrated, chromatographed on "Florisil" (Registered Trade Mark), eluted with methanol, adjusted to pH 1.0 with hydrochloric acid and the CF-1 recovered. Cosynthetic factor-1 is soluble in phenol and in water at pH > 6, insoluble in butanol, acetone, ether and water at pH 1-2; it contains the elements C = 50.33, H = 5.00, N = 12.18 and O = 32.49% by weight, empirical formula C14-15H17N3O7; melting point 280-285 DEG C.; the acid form has the infrared absorption spectrum shown in Fig. 1 and the ultraviolet absorption spectrum shown in Fig. 3. Specifications 775,115 and 863,419 are referred to.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式